GARDEN CITY, New York and KISSING, Germany, Sept. 11, 2013 /PRNewswire/ -- invendo medical GmbH, manufacturer and marketer of a novel single-use, computer-assisted colonoscopy system, announced that it has appointed Markus Fieber as Chief Operating Officer and Martin Giersiepen as Chief Technology Officer. Both bring substantial relevant expertise to strengthen invendo's industrializations activities.
(Logo: http://photos.prnewswire.com/prnh/20130311/NY73775LOGO )
Berthold Hackl, CEO of invendo medical, said, "We are excited for Markus and Martin to join invendo at this critical moment on our evolution to elevate our technical operations in support of our sales and marketing plans. We know that they will use their highly relevant expertise to make an immediate impact on our company as we begin to transition our invendoscopy system into routine clinical practice in the United States. Markus is a top operations professional who brings significant production management experience from around the globe, whilst Martin is a veteran product development executive who has advanced numerous products from lab to market."
NEW COO Markus Fieber will manage the production scale-up of invendo's single-use colonoscopy system. Mr. Fieber is an international executive with a senior level track record of more than 17 years in general management and production. He has comprehensive international working experience in Germany, UK, China and Mexico, working for world-class automotive suppliers including Bosch and Valeo where he served as General Manager and Plant Director respectively, as well as medical device companies such as Johnson & Johnson where he served as Managing Director. Key aspects of his expertise cover industrializing processes, reducing production costs, assuring quality and delivery performance and building successful teams. Fieber holds a PhD in mechanical engineering from the Technical University of Aachen.
New CTO Martin Giersiepen will focus on the industrialization of product and processes, while at the same time working on invendo's suite of next-generation products. Previously, Martin Giersiepen has been recognized for his important work researching blood damage caused by implants (Giersiepen Equation). During his career, he has held senior management positions at Beiersdorf, EOS, Braun (Gillette) and Soehnle, with a particular focus on diagnostic and consumer healthcare products. Under his tenure at Braun, the dental product group reached sales of more than € 2 billion. For mass-volume consumer product manufacturers Rowenta and Leifheit, he transferred more than 60 products from development to production at plants in Singapore, China and Mexico. Giersiepen was NPI Director with international R&D centers in California and the United Kingdom, and led the German site of Camera Dynamics/Vitec PLC as General Manager. He also holds a PhD in mechanical engineering from the Technical University of Aachen.
About the invendoscopyâ„¢ system
The invendoscopeâ„¢ offers benefits that are new to the field of colonoscopy including:
* A gentle procedure with lower forces on the colon wall that potentially reduces the need for sedation
* A single-use, disposable colonoscope with a working channel
* Computer-assisted ("robotic") gentle drive technology whereby the endoscope is not pushed or pulled
* All endoscopic functions are performed using a handheld device.
About Invendo medical - http://www.invendo-medical.com
Based in Garden City, N.Y., U.S.A. and Kissing (Munich), Germany, invendo medical develops disposable endoscopy products in the field of gastroenterology that are hygienic and employ "robotic" computer-assisted technology that allows for gentle advancement of the colonoscope which makes the procedure potentially pain-free for the patient, obviating or reducing the need for conscious sedation or anesthesia and thereby saving time and cost.
For more information, please see our website at http://www.invendo-medical.com and see our Youtube channel at http://www.youtube.com/user/invendomedical.
Editor: PR Wire
Copyright © ANTARA 2013
